Global Nuclear Medicine Market Research Report Information by Type (Diagnosis and Therapeutic ), by Application, by End User, and by Region

Description

List of Tables

Global Nuclear Medicine Market Research Report Information by Type (Diagnosis [SPECT Radiopharmaceuticals {Tc99m, I-123, and Others} and PET Radiopharmaceuticals {F18, C11 Choline, and Others}] and Therapeutic (Alpha Emitters [Actinium-225 (Ac-225), Radium-223 (Ra-223), and Others], Beta Emitters [Yttrium-90 (Y-90), Lutetium-177 (Lu-177), and Others], and Brachytherapy Isotopes [Iodine-125 (I-125) and Others]), by Application (Neurology, Cardiology, Oncology [Prostate Cancer, Breast Cancer, Lung and Bronchus Cancer, Thyroid Cancer, Colorectal Cancer, and Others], and Others), by End User (Hospitals & Diagnostic Centers, Research Institutes, and Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market Overview

In 2023, the nuclear medicine market was estimated to be worth USD 9.84 billion. The Nuclear Medicine Market industry is anticipated to expand from USD 10.63 billion in 2024 to USD 27.96 billion by 2032. Technological advancements in nuclear medicine and the increasing applications of radioisotopes in the healthcare industry are the primary factors driving market growth. Additionally, the nuclear medicine market is being driven by the expansion of public-private funding for the research and development of new techniques, as well as the increasing research and development in the pharmaceutical and biotechnology industries to improve radiotherapy for the accurate diagnosis of diseases such as thyroid-related diseases, respiratory diseases, bone diseases, neurological diseases, and others.

Market segment insights

The Nuclear Medicine Market has been divided into two categories: diagnostic and therapeutic. The Nuclear Medicine Market has been segmented into neurology, cardiology, oncology, and other fields based on application. The Nuclear Medicine Market has been categorized as hospitals & diagnostic centers, research institutes, and others based on the end user.

Regional Perspectives

The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. As a result of the availability of products and the presence of active industry participants in the region, North America accounted for the largest market share of 42.42% in 2023. The European market is expected to experience substantial growth during the forecast period because of the growing number of individuals suffering from heart disease, Alzheimer's disease, and neurological problems, as well as the increasing demand for improved diagnostic and treatment processes. Additionally, the nuclear medicine market is expanding because of the adoption of enhanced radiopharmaceuticals, new product introductions, and mergers and acquisitions. The market in Asia-Pacific is expected to experience rapid growth because of the increasing number of cardiac patients and the development of advanced imaging techniques that utilize diagnostic instruments such as PET and SPECT. Additionally, clinicians are being facilitated in their access to multiple 2D and 3D images using a gamma camera to perform SPECT imaging techniques, which is propelling the nuclear medicine market in the region. Moreover, the nuclear medicine market in Japan accounted for the largest market share in 2023, while the nuclear medicine market in India is the fastest-growing market in the Asia-Pacific region.

Major Players

Novartis AG (Switzerland), GE Healthcare (US), Cardinal Health (US), Eckert & Ziegler Group (Germany), Lantheus (US), Jubilant Radiopharma (Canada), Bayer AG (Germany), Siemens Healthineers (Germany), Curium Pharma (France), Bracco (Italy), and others are among the key companies in the Nuclear Medicine Market.

Product Code: MRFR/Pharma/5211-CR

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 RISING PREVALENCE OF CANCER AND OTHER CHRONIC DISEASES
- 4.2.2 TECHNOLOGICAL ADVANCEMENTS IN NUCLEAR MEDICINE
4.3 RESTRAINTS
- 4.3.1 SHORT HALF-LIFE OF RADIOPHARMACEUTICALS
- 4.3.2 SHORTAGE OF TRAINED MEDICAL PERSONNEL
4.4 OPPORTUNITY
- 4.4.1 USE OF RADIOPHARMACEUTICALS IN NEUROLOGICAL APPLICATIONS

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL NUCLEAR MEDICINE MARKET

6 GLOBAL NUCLEAR MEDICINE MARKET, BY TYPE

6.1 OVERVIEW
6.2 DIAGNOSTIC
- 6.2.1 SPECT RADIOPHARMACEUTICALS
  - 6.2.1.1 MO99/TC99M
  - 6.2.1.2 I-123
  - 6.2.1.3 OTHERS
- 6.2.2 PET RADIOPHARMACEUTICALS
  - 6.2.2.1 F18
  - 6.2.2.2 C11 CHOLINE
  - 6.2.2.3 OTHERS
6.3 THERAPEUTIC
- 6.3.1 ALPHA EMITTERS
  - 6.3.1.1 ACTINIUM-225 (AC-225)
  - 6.3.1.2 RADIUM-223 (RA-223)
  - 6.3.1.3 OTHERS
- 6.3.2 BETA EMITTERS
  - 6.3.2.1 YTTRIUM-90 (Y-90)
  - 6.3.2.2 LUTETIUM-177 (LU-177)
  - 6.3.2.3 OTHERS
- 6.3.3 BRACHYTHERAPY ISOTOPE
  - 6.3.3.1 IODINE-125 (I-125)
  - 6.3.3.2 OTHERS

7 GLOBAL NUCLEAR MEDICINE MARKET, BY APPLICATION

7.1 OVERVIEW
7.2 NEUROLOGY
7.3 CARDIOLOGY
7.4 ONCOLOGY
- 7.4.1 PROSTATE CANCER
- 7.4.2 BREAST CANCER
- 7.4.3 LUNG AND BRONCHUS CANCER
- 7.4.4 THYROID CANCER
- 7.4.5 COLORECTAL CANCER
- 7.4.6 OTHERS
7.5 OTHERS

8 GLOBAL NUCLEAR MEDICINE MARKET, BY END USER

8.1 OVERVIEW
8.2 HOSPITALS AND DIAGNOSTIC CENTERS
8.3 RESEARCH INSTITUTES
8.4 OTHERS

9 GLOBAL NUCLEAR MEDICINE MARKET, BY REGION

9.1 OVERVIEW
9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
- 9.2.3 MEXICO
9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 UK
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 INDIA
- 9.4.3 JAPAN
- 9.4.4 SOUTH KOREA
- 9.4.5 AUSTRALIA
- 9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
- 9.5.1 MIDDLE EAST & AFRICA
- 9.5.2 SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS,
10.3 COMPETITOR DASHBOARD
10.4 PUBLIC PLAYERS STOCK SUMMARY
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL
- 10.6.2 PARTNERSHIP
- 10.6.3 ACQUISITION
- 10.6.4 AGREEMENT
- 10.6.5 COLLABORATION
- 10.6.6 EXPANSION

11 COMPANY PROFILES

11.1 GE HEALTHCARE
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS/SERVICES OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 CARDINAL HEALTH
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 SWOT ANALYSIS
- 11.2.6 KEY STRATEGIES
11.3 CURIUM
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 KEY STRATEGIES
11.4 NOVARTIS AG
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 SWOT ANALYSIS
- 11.4.6 KEY STRATEGIES
11.5 LANTHEUS
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 KEY STRATEGIES
11.6 JUBILANT RADIOPHARMA
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 KEY STRATEGIES
11.7 SIEMENS HEALTHINEERS
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 SWOT ANALYSIS
- 11.7.6 KEY STRATEGIES
11.8 BAYER AG
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 SWOT ANALYSIS
- 11.8.6 KEY STRATEGY
11.9 ECKERT & ZIEGLER
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 KEY STRATEGIES
11.10 BRACCO
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGY

12 DATA CITATIONS